Crossject

Report Publication Announcement • Mar 1, 2018

Press release

Crossject announces its financial calendar 2018

Dijon, 1st March 2018

CROSSJECT (ISIN: FR0011716265; Ticker: ALCJ), a specialty pharma company developing a portfolio of innovative combined drugs for use in emergency situations, announces its projected financial calendar 2018.

Financial calendar 2018

• 20 March 2018* Annual results 2017
• 16 May 2018* Business update
• 17 May 2018 2018 Annual General Meeting
• 26 September 2018* Interim 2018 results
• 7 December 2018* Business update

* After trading

Contacts :

Crossject Patrick Alexandre info@crossject.com Investor contact CM-CIC Market Solutions Catherine Couanau +33 (0) 1 53 48 81 97 catherine.couanau@cmcic.fr

Press contact Buzz & Compagnie Mélanie Voisard +33 (0)3 80 43 54 89 melanie.voisard@buzzetcompagnie.com Audrey Lachat +33 (0)3 80 43 54 89 audrey.lachat@buzzetcompagnie.com

About CROSSJECT • www.crossject.com

Crossject (ISIN: FR0011716265; Ticker: ALCJ) is a specialty pharma company developing a portfolio of drugs for use in emergency situations (severe migraines, epilepsy, temporary paralysis, anaphylactic shock, overdoses, acute asthma attacks, etc.). With Zeneo®, its patented needle-free injection system, Crossject provides an efficient response to emergencies by enabling the simple self-administration of drugs. Crossject has been listed on the Euronext Growth market since February 2014.

Translation for information purposes only. In case of discrepancy between the French and English versions of this press release, only the French version should be deemed valid.